In an era of increasing antimicrobial resistance, Acinetobacter distinguishes itself as one of the most resistant Gram-negative bacteria responsible for significant morbidity and mortality. New solutions are needed to combat the detrimental effects of increasing rates of antimicrobial resistance. Using empiric broad-spectrum antibiotics in patients deemed at risk for infections caused by multidrug-resistant pathogens may protect against attributable mortality, but this temporary solution furthers the risk of antimicrobial resistance. In this article we will review relevant strategies to aid with early identification and appropriate treatment of Acinetobacter pneumonia while preserving antibiotic susceptibility.
Respiratory infections are among the leading causes of death from infectious diseases worldwide [1] . Escalating rates of antibiotic resistance add substantially to the morbidity, mortality, and costs related to pneumonia, especially in the intensive care unit (ICU) setting [2] . More than 700 000 healthcare-associated infections, many caused by antibiotic-resistant bacteria, occur annually in the United States [3] . Corrado et al recently reported their experience with 283 927 cases of pneumonia in New York City hospitals from 2010-2014 [4] . Community-acquired pneumonia (CAP) was most common (54.3%), followed by healthcare-associated pneumonia (HCAP; 30.2%), hospital-acquired pneumonia (HAP; 14.0%) and ventilator-associated pneumonia (VAP; 1.6%). Escalating antibiotic resistance (especially in HCAP, HAP, and VAP) has primarily impacted the outcomes of patients with pneumonia by increasing the administration of inactive empiric treatment (IET; ie, an antimicrobial regimen that is not active against the pathogen based on in vitro susceptibility testing) [5] . Indeed, global trends for specific infectious diseases have shown decreasing mortality across the spectrum of infections, with those attributed to antibiotic-resistant bacteria being a glaring exception [6] .
Acinetobacter species are now recognized as one of the most important causes of infection due to Gram-negative bacteria (GNB) in hospitalized patients because of the high levels of antibiotic resistance and mortality associated with this pathogen [7] . Most clinical infections are attributed to Acinetobacter calcoaceticus-Acinetobacter baumannii complex (ABC), which is comprised of 4 species; A. baumannii, Acinetobacter nosocomialis, and Acinetobacter pittii cause clinical infections in humans, whereas A. calcoaceticus is an environmental organism of negligible clinical importance [8] . Acinetobacter baumannii is the most common species in most regions; the prevalence of A. pittii and A. nosocomialis is higher in Southeast Asia, and A. pittii may be more common in Scandinavian countries [8, 9] .
Community-acquired pneumonia attributed to ABC has been described throughout the world, including North America, but is most common in tropical and subtropical locations (eg, Central/ South America, Southeast Asia) [10, 11] . However, most cases of ABC pneumonia occur among hospitalized patients with either HAP or VAP [12] . Antibiotic resistance, including resistance to carbapenems, among ABC pneumonia isolates is common and associated with higher rates of IET and greater hospital mortality [13] . A recent review from Southeast Asia found evidence of a dose-response relationship between different degrees of antibiotic resistance and excess mortality due to ABC infections, including pneumonia, with the odds for mortality being 1.23 for multidrug-resistant (MDR) ABC, 1.72 for extensively drug-resistant (XDR) ABC, and 1.82 for pandrug-resistant (PDR) ABC [14] . Most concerning is a recent study from Europe demonstrating that almost half of all ABC VAP isolates are colistin resistant [15] . Repetitive element sequence-based polymerase chain reaction (PCR) confirmed a predominant clonal lineage, suggesting the presence of an epidemic XDR/PDR ABC clone spreading throughout Europe [15] .
Premier Research Database (2009-2013), 1 study of 175 US hospitals examined adults with pneumonia or sepsis attributed to ABC [17] . Among 1423 patients with ABC infection, 1171 (82.3%) had MDR ABC. Those with MDR ABC were more likely to receive IET than those with non-MDR ABC infection (76.2% vs 13.8%; P < .001). Moreover, MDR ABC strongly predicted receipt of IET, which was associated with higher hospital mortality. These same investigators also demonstrated that, among patients with ABC pneumonia or sepsis, each day's delay in instituting active treatment added $1344 to the cost of hospitalization [18] .
The challenge to clinicians is how to balance the need for administering active treatment to improve patient outcomes with the need to avoid unnecessary use of broad-spectrum antibiotics that could further escalate resistance emergence. Rapid diagnostic tests (RDTs) are developing as a means to accomplish this important balance. The evolving RDTs include multiplex real-time PCR, other nucleic acid detection techniques, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), fluorescence in-situ hybridization, automated microscopy, and analysis of exhaled compounds [19] . Each technique has limitations, and most have not been validated for respiratory secretions. Nevertheless, they offer the potential for more targeted treatment by providing pathogen identification and either identification of specific resistance genes (molecular methods) or rapid availability of pathogen susceptibility (automated microscopy methods). To date, the available data suggest that application of RDTs combined with antimicrobial stewardship can improve patient outcomes [20, 21] . The challenge will be to develop effective strategies that apply these techniques to cases of suspected and proven ABC pneumonia.
Wenzler et al evaluated the clinical and economic impact of using MALDI-TOF MS along with antimicrobial stewardship in patients with ABC pneumonia and/or bacteremia [22] . They found that the combination of more rapid ABC identification and stewardship significantly reduced the median time to active empiric treatment (AET) compared with conventional identification without stewardship. This intervention was also associated with greater clinical cure, decreased length of stay, and lower hospital costs. The recognized complexity of infections attributed to ABC and other antibiotic-resistant bacteria has led to the finding that expert input by infectious disease specialists in the management of these infections may improve outcomes [23] . Such expertise is more likely to be needed for ABC pneumonia, given rising antimicrobial resistance as well as the availability of new RDTs [13, 19, 22, 24] .
To further illustrate the potential benefit of RDTs in the management of ABC pneumonia, we created a model focusing on VAP attributed to carbapenem-resistant ABC (CRABC) (Figure 1 ). In this model we compare the relative survival benefit when RDTs are used versus empiric treatment with meropenem. The potential benefit of RDTs was calculated only for patients with ABC pneumonia, regardless of the presence of other microbial species. Based on current literature estimates, the contribution of ABC to VAP varies according to region, with the lower estimated rates being approximately 8% (11.4% of all GNB) [7, 17] . Current meropenem resistance also varies among countries, so we used a proportion of 49% among ABC isolates as a conservative estimate [25] . Based on our experience, which is corroborated by published reports, we used a mortality rate in ABC VAP of 61.5% when IET was administered and 25% with AET [5, 13, 26] . To derive the true-positive and false-negative rates in detecting ABC, we reviewed published operating characteristics for PCR and automated microscopy diagnostics [27] [28] [29] . Our model showed a significant improvement in the relative survival of VAP caused by CRABC. Of note, many institutions are confronted with a higher prevalence of MDR ABC. The relative survival rates would be even more favorable if the rate of MDR ABC increased, rendering empirical treatment more inactive, or if the RDT characteristics improved, thereby decreasing the number of false negatives. For instance, if meropenem resistance were 80%, then the relative survival in ABC VAP would increase to 5.6 times with the use of RDTs.
ANTIBIOTIC TREATMENT: EMPIRIC CONSIDERATIONS
To date there are no large randomized controlled trials focused on delineating the optimal empiric therapy for pneumonia caused by MDR ABC. Therefore, empiric treatment choices remain primarily guided by expert opinion and in vitro methods. When selecting empiric antimicrobial therapy, consideration should be given to the distribution of the potential offending GNB, including ABC, and the local susceptibility patterns (ie, local antibiogram), as well as the potential long-term consequences of escalating antimicrobial resistance [30] .
First, empiric antimicrobial coverage for ABC is indicated in critically ill septic patients hospitalized in ICUs with a high prevalence of ABC infections and in previously colonized patients ( Figure 2 ). When carbapenem resistance rates exceed a certain threshold, empiric combination regimens should be used, as recommended by the newly formed Acinetobacter baumannii task force [31] (Figure 2 ). For presumed susceptible isolates, carbapenems (except for ertapenem, which does not exhibit activity against ABC) remain the primary choice. Recent data have emphasized the relevance of minimium inhibitory concentrations (MICs) to carbapenems among ABC isolates. Two recent trials demonstrated greater risk of mortality with the empiric use of carbapenems when treating bacteremia caused by ABC isolates with MICs ≥ 8mg/L [32, 33] .
When infection with CRABC is suspected, empiric combination therapy should be used until susceptibilities are known. Many combination regimens have been proposed, and Supplementary Table 1 summarizes the most relevant ones with in vivo studies supporting them. Because polymixins remain the drugs with the greatest level of in vitro activity against CRABC among currently approved antibiotics, they are favored as the backbone of most empiric treatment regimens. To date, there are no compelling data favoring one colistin combination regimen over another. A retrospective study that enrolled 236 patients with XDR ABC pneumonia (susceptible to colistin and tigecycline only) found that 3 colistin-based regimens (colistin with sulbactam, tigecycline, or carbapenem) offered equivalent clinical outcomes [34] . Similarly, an analysis of 250 patients with bacteremia caused by XDR ABC found that colistin combinations were associated with lower hospital mortality compared with monotherapy (52% vs 72%; P = .03) after propensity-score matching [35] . Numerous other non-colistinbased combinations, including sulbactam, aminoglycosides, and tigecycline, have also been described, with inconsistent results making these salvage options in carbapenem-and colistin-resistant ABC pneumonia [36, 37] .
It is also crucial to optimize drug delivery to the lung with adequate dosing when treating ABC pneumonia. Because of its longer half-life, colistin requires a loading dose to achieve timely therapeutic levels [38] . Table 1 summarizes recommended antibiotic dosing in ABC pneumonia. Higher doses of colistin may be needed in critically ill patients with obesity, augmented renal clearance, or continuous renal replacement therapy and with pathogen MICs > 0.5 µg/dL. Optimal tigecycline use is also The model focuses on the survival benefit for VAP attributed to ABC only and does not calculate the survival benefit for any other microbes. The probability of survival or death for each branch point equals the rate of ABC infection multiplied by the rate of active empiric therapy (AET) or inactive empiric therapy (IET) multiplied by the success (survival) or failure (death) rates when AET or IET are administered. Sensitivity and specificity estimates for RDDT are based on reported estimates from molecular methods and automated microscopy [27] [28] [29] . Meropenem resistance rates and survival rates when AET and IET are used were extrapolated from the literature and the experience at Barnes-Jewish Hospital in St Louis [5, 13, 26] . For true-positive results from RDDT, the survival rate equals the survival rate when AET is used. For false-negative results from RDDT, the survival rate equals the survival rate when IET is used. It is important to recognize that our model is based on certain assumptions. We assumed that the delay in administering antibiotics associated with RDDT does not significantly impact survival. This may not be true in all circumstances, especially when septic shock is present. We also assumed that positive tests will be treated with AET and that false-negative tests will be treated with IET. Additionally, we assumed an ABC rate of 11.4%, an ABC meropenem resistance rate of 49%, an RDDT sensitivity of 95%, an RDDT specificity of 95%, a survival rate with AET of 75%, and a survival rate with IET of 38.5%. Abbreviation: GNB, Gram-negative bacteria.
complicated by the necessity for higher doses. Studies in VAP and other serious infections based on the currently approved dosing schedule demonstrated higher mortality relative to comparators [39, 40] . Newer evidence suggests that higher doses of tigecycline (200 mg followed by 100 mg twice a day) could offer equivalent outcomes to imipenen in pneumonia, although the number of ABC isolates studied was small [41] .
ANTIBIOTIC TREATMENT: DEFINITIVE CONSIDERATIONS
Combination regimens serve an important role as empiric therapy allowing for broader initial coverage until susceptibilities are known. It remains unclear whether they provide any additional benefit once definitive therapy is administered. Despite in vitro studies demonstrating synergy among various antimicrobials, clinical trials have failed to show a significant impact of definitive combination therapy on mortality [42] [43] [44] . Colistin has been combined with carbapenems, sulbactam, tigecycline, rifampicin, fosfomycin, and glycopeptides, and other noncolistin combination regimens have also been examined. In general, combination regimens seem to provide better clinical and microbiological cure rates but without a compelling decrease in mortality. In a study by Durante-Mangoni et al, 209 patients with pneumonia (70% VAP, 8.6% HAP) attributed to CRABC were randomized to colistin alone or colistin plus rifampicin [43] . Microbiological eradication was higher in the combination arm, but infection-related death at 30 days was not significantly different. A study from Greece of VAP caused by XDR ABC also found similar 28-day mortality rates for colistin-based combinations (mostly with a carbapenem) and monotherapy [44] .
It is unclear whether the discrepancy between clinical/ microbiological improvement and lack of survival benefit stems solely from the available inadequately powered studies. The largest effect on mortality likely results from the timing of AET. Recruiting patients after culture results and susceptibility data become available may alter the effect antibiotics have on mortality by delaying AET. Rapid diagnostic tests could assist with earlier AET administration during the initial stages of infection. Trying to circumvent the small number of patients studied, meta-analyses have been performed. Unfortunately they rely mainly on heterogeneous observational studies, both in terms of outcome definitions and antibiotic treatments used. These meta-analyses also failed to find a benefit of combination therapy over monotherapy when looking at both colistin-and sulbactam-based regimens [45, 46] . The most recent meta-analysis examining this issue found no overall mortality benefit with colistin-based combination regimens over monotherapy [47] . However, when studies stratified according to the dosing of colistin were evaluated, those combination regimens using high-dose colisitn (defined as a daily mean/median colistin dose > 6 million international units) were associated with a mortality advantage, which emphasizes the importance of antibiotic dosing for ABC infections.
When deciding upon which single agent should be selected for step-down definitive therapy, location of the infection, severity of the infection, and MIC of the isolated bacterium should be taken into consideration. With a susceptible ABC, the initial combination therapy can be reduced to a narrower spectrum antibiotic. If the isolate is a CRABC, sulbactam and the newer antibiotics may be favored over tigecycline or colistin monotherapy. Supplementary Table 2 summarizes the available single-agent studies. Few studies compared single antibiotics as definitive therapy in pneumonia caused by XDR ABC. When faced with a colistin-or tigecycline-susceptible only strain, combination therapy is appropriate to prevent emergence of resistance or heteroresistance.
Even though the trial by Durante and colleagues did not report any new cases of resistance in the colistin arm, the short duration of follow-up and exclusion of previous exposures to colistin preclude any generalization about resistance [43] . In another study, colistin resistance emerged in a significant proportion of the cases, and resistance to tigecycline also occurred while patients were on treatment [36] . The clinical consequences of colistin heteroresistance are unclear, but it seems that heteroresistance is linked to prior colistin administration and is associated with higher treatment failure rates [48, 49] . Pharmacokinetic/pharmacodynamic data also suggest that bacterial regrowth occurs irrespective of the colistin regimen used [50] . Moreover, mutant-preventing concentrations of antibiotics for ABC are greater than the usually obtained therapeutic concentrations, especially for agents like colistin that have limited pulmonary tissue penetration [51] .
Use of tigecycline unaccompanied by other antimicrobials may lead to resistance and clinical failure, so it should not be used as monotherapy for ABC infections [36] . When compared with colistin, in a matched cohort study of 294 patients with MDR ABC pneumonia, tigecycline carried an excess mortality of 16.7% in isolates with MICs >2 μg/mL [52] . Many trials have compared combination therapies for MDR ABC infections, and their results have typically been extrapolated to the backbone antibiotic used. In general, these studies suggest a trend toward better outcomes and less toxicity for sulbactam-based regimens compared with colistin-based regimens used for definitive therapy (Supplemental Table 2 ). Minocycline has also emerged as a potential viable treatment for ABC pneumonia [53, 54] .
A recent systematic review of minocycline for ABC found pneumonia to be the most common infection and 100 mg twice daily to be the most common dose with or without a loading dose of 200 mg (most patients received a loading dose) [55] .
Overall, the clinical success rate of monotherapy or combination treatment with minocycline was 78.2%, and microbiological cure ranged 50%-89%. 
NEW ANTIBIOTICS
Multidrug-resistant ABC remains largely unaddressed by the new antibiotics recently approved and in development. Most trials of new antibiotics targeting GNB have been conducted in complicated urinary tract or intra-abdominal infections, so generalization to pneumonia may be premature. Plazomicin is a new aminoglycoside that seems to outperform colistin in infections caused by carbapenem-resistant GNB [56] . However, limited lung penetration, as well as resistance emergence due to currently expressed ribosomal methyl transferases, will limit its utility for ABC pneumonia [57] . Eravacycline, a new tetracycline, displayed better MICs than minocycline and tigecycline for ABC isolates and remained the strongest antibiotic against CRABC in in vitro studies [58] . However, eravacycline has not yet been studied in ABC pneumonia.
The most promising new antibiotic for ABC pneumonia is cefiderocol, which has shown excellent in vitro activity against ABC strains [59] . Cefiderocol is a parenteral siderophore cephalosporin that promotes formation of a chelated complex with ferric iron and facilitates its transport across the outer membrane of GNB using their receptor-mediated bacterial iron transport systems [60] . A recent study of world-wide clinical isolates of MDR ABC found the MIC50 for cefiderocol to be 0.25 μg/mL [61] . Similarly, a study from Greece found the cefiderocol MIC90 for MDR ABC to be 0.5 μg/mL among 107 clinical isolates tested, and cefiderocol had better MIC distributions compared with tigecycline and colistin [62] .
PULMONARY PENETRATION OF PARENTERAL ANTIBIOTICS FOR ACINETOBACTER CALCOACETICUS-ACINETOBACTER BAUMANNII COMPLEX PNEUMONIA AND AEROSOLIZED ANTIBIOTICS
Pharmacokinetic/pharmacodynamic characteristics are increasingly recognized to be important determinants of outcome for patients with serious infections, including pneumonia. However, for patients with ABC pneumonia, there is the added complexity of lung penetration of the antimicrobial agents for this highly resistant pathogen. Studies in critically ill patients have shown that epithelial lining fluid (ELF)-to-plasma concentrations of systemically administered antibiotics used for ABC-susceptible isolates can range from high mean values of 104% ± 9% for cefepime (2 g as a 0.5-h infusion followed by 4g/24 h intravenous continuous infusion), to an intermediate mean value for meropenem of 82% ± 223% (2 g or 500 mg intravenously as a 3-h infusion every 8 h or 1 g intravenously as a 0.5-h infusion every 8 h), to a low value of 12% for tobramycin (7-10 mg/kg intravenously once daily) [63] . Colistin penetration into the lung is also at the low range, with 1 study of VAP demonstrating undetectable levels in bronchoalveolar lavage fluid [64] .
Given the poor or variable lung penetration of many of the antibiotics typically used for ABC pneumonia, aerosolized delivery of antibiotics has been looked to as a therapeutic alternative (Supplementary Table 3 ). In a recent neutropenic mouse model of ABC pneumonia, the area under the concentration-time curve over 24 hours divided by the MIC (AUC/MIC) in the ELF was the most predictive pharmacokinetic/pharmacodynamic index for aerosolized colistin [65] . These results are consistent with the findings in humans showing that there is higher antimicrobial efficacy after aerosol delivery of colistin compared with intravenous administration [66] . Several meta-analyses of primarily observational trials have found the use of aerosolized colistin combined with intravenous colistin compared with intravenous therapy alone to be associated with improved bacterial eradication from the lung, greater clinical cure rates, and lower mortality [67, 68] . A post hoc analysis of the inhaled amikacin-fosfomycin trial for VAP examining PDR ABC isolates also found greater ventilator-free days and clinical cure at day 14 in patients receiving aerosolized therapy [69] .
CONCLUSIONS
Acinetobacter calcoaceticus-Acinetobacter baumannii complex pneumonia has become an increasingly recognized infection in critically ill patients. The high rates of resistance to most commonly prescribed antimicrobials make selection of AET in ABC pneumonia challenging. Moreover, there are current limitations in our clinical ability to routinely detect the genetic mechanisms of resistance and the presence of multiple subspecies of ABC. Nevertheless, the availability of RDTs and new antibiotics with greater activity against ABC strains offers the prospect for improved management and outcomes for ABC pneumonia.
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